Quality and Authenticity Control of Functional Red Yeast Rice—A Review

Jiawen Song †, Jia Luo †, Zhubing Ma, Qiang Sun, Chunjie Wu * and Xiaofang Li *

School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; Songjiawen@stu.cdutcm.edu.cn (J.S.); ljjl6610@sina.com (J.L.); 18280322839@163.com (Z.M.); sunqiang@stu.cdutcm.edu.cn (Q.S.)
* Correspondence: wucjcdtcm@163.com (C.W.); lixiaofang918@163.com (X.L.); Tel./Fax: +86-28-6180-0234 (X.L.)
† These authors contributed equally to this work.

Received: 3 April 2019; Accepted: 17 May 2019; Published: 20 May 2019

Abstract: Red yeast rice (RYR) is made by fermenting the rice with Monascus. It is commonly used in food colorants, dyeing, and wine making in China and its neighboring countries. Nowadays RYR has two forms on the market: common RYR is used for food products, the other form is functional RYR for medicine. However, some researchers reported that commercial lovastatin (structure is consistent with monacolin K) is illegally added to common RYR to meet drug quality standards, so as to imitate functional RYR and sell the imitation at a higher price. Based on current detection methods, it is impossible to accurately distinguish whether functional RYR is adulterated. Therefore, it is especially important to find a way to authenticate functional RYR. In the current review, the advances in history, applications, components (especially monacolins, monacolins detection methods), quality standards, authentication methods and perspectives for the future study of RYR are systematically reviewed.

Keywords: functional RYR; monacolin K; detection methods; quality standards; authentication methods

1. Introduction

1.1. The History and Development of RYR

RYR, which is solid-fermented by artificial inoculation of Monascus purpureus on steamed rice [1], has been widely used for thousands of years by China and its neighbors. It has various names in different cultures [2]. For example, it is called Chiqu, Hongqu, Red rice, Fuqu, etc., in China; Koji, AngKhak, Beni-Koji, and Red-Koji in Japan; Rotschimmelreis in Europe; and Red Mold or Red mold rice in the USA. In ancient times, Fujian, Zhejiang, and Taiwan were considered to be the places of origin of RYR, especially Gutian (a town in Fujian province) which has been confirmed as the genuine origin of RYR because of the high quality and production there [3,4]. The earliest record of RYR has it being used as a food flavoring, colorant, and brewing agent, such as in fermented bean curd, pork stew, roast meat products, and rice wine [5]. Subsequently, the ancients discovered that RYR has therapeutic effects. The therapeutic effects have been recorded in the Compendium of Materia Medica, an ancient Chinese pharmacopoeia written by Li Shizhen during the Ming dynasty [6], which narrated in detail how RYR has “the effect of promoting the circulation of blood and releasing stasis, invigorating the spleen and eliminating digestion.”

Since 1979, monacolin K, which can lower lipids in blood, has been extracted from Monascus species [7]. Nowadays, RYR comes in two forms on the market [8]: common RYR, which is used as a source of natural pigments for coloring in the food and textile industries. The fermentation conditions of common RYR are relatively quick and simple. According the “Food additives Red
1.2. Monacolins in RYR

RYR contains several types of secondary metabolites that have biological activity, including *Monascus* pigments, monacolins, gamma-aminobutyric acid, dimeric acid, enzymes, polysaccharides, ergosterol, polyketides, unsaturated fatty acids, phytosterols, isoflavones, alkaloid, and trace elements [15–17]. Secondary metabolites in RYR have been shown to have biological activities through modern pharmacological experiments. For instance, *Monascus* pigments (MPs) are usually used as colorants in the food and textile industries, but research has also demonstrated that they can have effects such as anti-obesity, lipid-lowering and attenuating nonalcoholic fatty liver disease in mice [18–20]. On the other hand, in RYR, there is a compound named citrinin that is a highly toxic, mutagenic, and carcinogenic metabolite [21]. It is worth noting that monacolin K has been researched in depth [22].

1.2.1. Physical and Chemical Properties of Monacolin K

Monacolin K is the first reported lipid-lowering component to be isolated from *Monascus purpureus* [23]. Monacolin K, which appears as colorless crystals, is soluble in methanol, ethanol, acetone, chloroform, and benzene but not soluble in n-hexane or petroleum ether. The boiling point is 157–159 °C and the [α]D25 value is +307.6 °C (in methanol). The molecular formula is C24H36O5 (Mw 404) and the ratio of C:H:O is 71.31:8.91:19.78, obtained by elemental analysis and high-resolution mass spectroscopy. The Rf value in TLC is 0.47 in dichioromethane: acetone (4: 1, v/v). The UV spectrum (methanol) showed maxima at 229, 237, and 246 nm. The IR spectrum (KBr) showed absorption bands at 3550, 2970, 1696, and 1220 cm−1. The 13C-NMR spectrum (CD3OD) indicated the presence of two ester carbonyl carbons, four methyl carbons and methylene and methine carbons. The mass spectrum peaks (m/e) are at 404 (M+), 302 (M – 102), 284 (M – 120), and 224 (M – 180), and prominent peaks in the mass spectrum of monacolin K were observed at 198 (M – 206), 172 (M – 232), 159 (M – 245), and 157 (M – 247) [7]. There are two chemical structures in functional RYR, shown in Figure 1, the acid and lactone forms of monacolin K.

![Figure 1. The two structures of monacolin K. (a) the lactone form; (b) the acid form.](image)

1.2.2. The Mechanism of Lipid Lowering of Monacolin K

The mechanism of lipid lowering of monacolin K is shown in Figure 2 [24]: competitively inhibiting endogenous cholesterol synthesis speed limit enzyme (3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in cholesterol biosynthesis in animals and humans), blocking the pathways of hydroxyl valeric acid metabolic in cells, reducing cholesterol synthesis...
in the cell, stimulating the quantity and activity of LDL receptors on the cell membrane surface, and removing the serum cholesterol. RYR can also inhibit the absorption of cholesterol, and the active ingredient may be sterols [24]. In the procedure, the mean serum total cholesterol (TC) and triglyceride (TG) levels decline and the low-density lipoprotein (LDL, the bad lipoprotein) level decreases significantly, but the high-density lipoprotein (HDL, the good lipoproteins) level does not change much [25]. The acid form is the efficient form because its structure is similar to that of HMG-CoA, shown in Figure 3, and can directly inhibit the synthesis of cholesterol [26]. Therefore, the lactone form needs to be hydrolyzed into an acid structure by the action of the hydroxyl esterase in the body, and then to be functionalized.

\[
\text{Acetyl CoA} + \text{Acetoacetyl CoA} \rightarrow \text{HMG-CoA} \rightarrow \text{HMG-CoA Reductase} \rightarrow \text{Red yeast rice (Monacolin K)}
\]

![Figure 2. RYR effects on cholesterol biosynthesis.](image)

\[
\text{Monacolin K acid} + 2\text{NADPH} \rightarrow \text{HMG-CoA reductases} \rightarrow \text{R}-\text{Mevalonic acid}
\]

![Figure 3. The HMG-CoA reductase reaction and the competitive inhibition of monacolin K acid.](image)

1.2.3. Monacolin Analogs

In addition, there are reports showing that there are other monacolins in RYR [27]. Evaluating the activity of newly discovered compounds in vitro, new monacolins extracted from RYR had a similar lipid-lowering effect to monacolin K [28]. In the 1980s, Endo isolated monacolin J, L, X, M, and dihydromonacolin L from Monascus purpureus, and proved that all of them also could inhibit HMG-CoA reductase and reduce the serum LDL and TC levels [29–31]. In 2004, Li et al. [32] identified 14 monacolin compounds such as monacolin K, J, L, M, X, and their hydroxy acid form, as well as dehydromonacolin K, dihydromonacolin L, compactin, 3α-hydroxy-3,5-dihydromonacolin L, etc. in RYR. In 2006, Dhale et al. [33] separated dihydromonacolin MV in RYR. In 2011 and 2013, Liu et al. [34,35] isolated monacophenol, monacolin O and P from RYR. In 2012, Zhu et al. [36] extracted two new dehydromonacolins (dehydromonacolin N, J) and detected 10 other monacolins.
(α,β-dehydrodihydromonacolin K, L, and the ethyl ester of monacolin K, etc.) from RYR. In 2016 Zhang et al. [15] obtained new five monacolins, including monacolin K, α,β-dehydro-monacolin Q, monacolin Q, α,β-dehydro-monacolin S, and monacolin S. In 2017, Zhang et al. [37] found four new monacolins, including monacolin T, monacolin U, 6α-O-methyl-4,6-dihydromonacolin L, and 6α-O-ethyl-4,6-dihydromonacolin L. The chemical structures of the monacolins investigated in RYR are shown in Table 1. What is even more remarkable is that Li et al. [38] isolated more than 80 kinds of monacolins from the RYR product Xuezhikang and established a database of more than 720 potential monacolins, providing a potential effective method for the discovery of new analogous series, and offering a material basis for the further exploitation of RYR products.

| Name | Type | Structure | Formula | MW | Activity | Ref. |
|------|------|-----------|---------|-----|----------|------|
| Monacolin | K | | C23H36O5 | 404 | Lipid lowering | |
| | J | OH | C23H32O4 | 322 | Lipid lowering | |
| | L | H | C23H32O3 | 304 | Lipid lowering | |
| | X | | C24H38O5 | 422 | Lipid lowering | |
| | M | | C24H36O7 | 436 | Lipid lowering | |
| | K acid form | | C24H36O7 | 404 | Lipid lowering | |
| | J acid form | OH | C24H36O4 | 338 | Lipid lowering | |
| | L acid form | H | C24H36O3 | 322 | Lipid lowering | |
| | X acid form | | C24H36O7 | 436 | Lipid lowering | |
| | M acid form | | C24H36O7 | 424 | Lipid lowering | |
| | T | -CH3 | C23H36O5 | 368 | Anti-tumor | [37] |
| | U | -CH2CH3 | C22H36O5 | 382 | Anti-tumor | |
| | O | | C24H36O8 | 468 | Anti-tumor | [35] |
| Monacolin | P | | C26H46O6 | 484 | Anti-tumor | |
| | Q | | C19H22O2 | 282 | Anti-tumor | [15] |
Table 1. Cont.

| Name                        | Type                      | Structure | Formula     | MW  | Activity         | Ref. |
|-----------------------------|---------------------------|-----------|-------------|-----|------------------|------|
| S                           |                           |           | C_{23}H_{35}O_{7} | 438 | Anti-tumor       | [15] |
| Monacolin                   |                           |           |             |     |                  |      |
| R                           |                           |           | C_{19}H_{23}O_{3} | 304 | Anti-tumor       |      |
| K                           | Dehydro-monacolin         |           | C_{20}H_{34}O_{4} | 386 | Lipid-lowering   | [32] |
| N                           |                           |           | C_{20}H_{34}O_{4} | 344 | Anti-tumor       | [36] |
| L. H                        | Dihydro-monacolin         |           | C_{19}H_{35}O_{3} | 306 | Lipid-lowering   | [32] |
| J. OH                       |                           |           |             |     | Anti-tumor       |      |
| K                           | α,β-dehydrodihydro-monacolin |           | C_{19}H_{35}O_{2} | 288 | Anti-tumor       | [36] |
| L. H                        |                           |           | C_{20}H_{35}O_{4} | 388 | Anti-tumor       |      |
| the ethyl ester of monacolin K | -CH_{2}CH_{3}            |           | C_{20}H_{45}O_{6} | 450 |                  | [36] |
| the methyl ester of the hydroxyl acid form of monacolin K | -CH_{3} |           | C_{20}H_{46}O_{6} | 436 |                  |      |
| 6α-O-ethyl-4,6-dihydro-monacolin L | -CH_{2}CH_{3}            |           | C_{21}H_{44}O_{4} | 350 | Anti-tumor       | [37] |
| 6α-O-methyl-4,6-dihydro-monacolin L | -CH_{3} |           | C_{20}H_{42}O_{4} | 336 | Anti-tumor       |      |
### Table 1. Cont.

| Name                                           | Type                 | Structure | Formula  | MW | Activity                     | Ref. |
|------------------------------------------------|----------------------|-----------|----------|----|------------------------------|------|
| 3α-hydroxy-3,5-dihydro-monacolin L             | C19H28O4             | 322       | Lipid-lowering |   |                              | [15] |
| 3β-hydroxy-3,5-dihydro-monacolin L             | C19H26O3             | 300       | Lipid-lowering |   |                              | [15] |
| α,β-dehydro-monacolin S                        | C23H34O5             | 420       | inhibition of cancer cell proliferation |   |                              | [15] |
| α,β-dehydro-monacolin Q                        | C23H34O5             | 390       | Lipid-lowering |   |                              | [32] |
| Compactin                                      | C24H38O5             | 390       | Lipid-lowering |   |                              | [34] |
| Monacophenyl                                   | C19H26O3             | 302       |          |    |                              | [35] |
| Dihydro-monacolin MV                           | C24H38O5             | 406       | 2,2-diphenyl-1-picyrylhydrazyl (DPPH) radical scavenging activity |   |                              | [33] |

1.3. The Biosynthetic Pathway and Sources of Monacolin K

There are few studies about the biosynthetic pathway of monacolin K generated by Monascus purpureus, it is just speculated that this pathway may be similar to the synthetic pathway of monacolin K in Aspergillus terreus [39]. Aspergillus terreus has been frequently utilized to figure out the synthesis of
monacolin K [40]. The synthetic pathway of monacolin K in *Aspergillus terreus*, shown in Figure 4 is as follows: (1) the lovastatin nonaketide synthase (LNKS) catalyzes the synthesis of one molecule of malonyl CoA in condensation reaction with nine molecules of acetyl CoA, generating dihydromonacolin L (a nonaketide compound) that is a main structure of monacolin K, then it formed monacolin L by oxidation, dehydration, and other steps, and finally monacolin J is generated through single oxygenase catalytic hydroxylation reaction; (2) the lovastatin diketide synthase (LDKS) catalyzes the condensation of one molecule of malonyl CoA with two molecules of acetyl CoA to form methylbutyryl CoA; (3) under the action of the transesterase, methylbutyryl CoA is linked to monacolin J with an ester ether bond to complete the synthesis of monacolin K.

Meanwhile, commercial lovastatin appeared as a lipid-lowering drug in the pharmaceutical market with the permission of the FDA in 1986. The sources of commercial lovastatin mainly contain two synthetic approaches. The first is that utilize submerged fermentation (SmF) of *Monascus purpureus* and *Aspergillus terreus*, adding carbon and nitrogen source (such as glucose, oat meal, and corn steep liquor) to medium with *Monascus purpureus* and *Aspergillus terreus*, after appropriate fermentation, then obtaining lovastatin via separation and purification; the other is chemical synthesis, replacing the decaline ring of the fungal compounds with an aromatic ring, like fluvastatin and atorvastatin [41,42]. Early studies have shown that the structure of monacolin K is chemically identical to that of commercial lovastatin [32].

In common RYR, monacolin K cannot be produced or is very tiny in a short and simple process of fermentation. Recently researchers reported that commercial lovastatin is added to common RYR to imitate functional RYR and therefore obtain more profits [43,44]. This phenomenon has inhibited the development of functional RYR, and more important, long-term use of lovastatin probably can cause burnout, gastrointestinal reactions, myalgia, etc. About 10–15% patients with dyslipidemia who take statins experience skeletal muscle problems [11].
2. The Detection Methods of Monacolin K of RYR

Due to the lipid-lowering activity, monacolin K is used as a quality control indicator of RYR. The detection methods for monacolin K in RYR are shown in Table 2, mainly including HPLC, HPLC-MS/MS, GC-MS, and so on, and the analysis instrument, measurements conditions, and detection indicators are described in detail.
### Table 2. The detection methods of monacolin K of RYR.

| Detection Methods | Detection Conditions | Column | Detector | Detection Index | Ref. |
|-------------------|----------------------|--------|----------|-----------------|------|
| HPLC | Acetonitrile:Water (45:55, v/v); pH was adjusted to 2.5 with H$_3$PO$_4$; 1 mL/min | Nucleosil C-18 | UV detector; 238 nm | Monacolin K (lactone) | [45] |
| HPLC (Shimadzu) | Acetonitrile:10 mM Phosphate buffer solution (60:40, v/v), pH was adjusted to 3.5 with 10% H$_3$PO$_4$; 1 mL/min | Millennium Sil C-18 (125 × 4.6 mm, 5 µm) | UV-visible detector; 236 nm | Monacolin K (lactone) | [46] |
| HPLC (Shimadzu 10A) | Methanol:0.1% Phosphate (72:28, v/v), isocratic elution for 25 min, linear elution with 100% methanol until 30 min; 0.5 mL/min; 40 °C | Wakosil-II 5C18 (250 × 4.6 mm, 5 µm) | UV detector; 238 nm | Monacolin K (lactone) and citrinin | [47] |
| HPLC (Agilent 1200) | Acetonitrile:Water (55:45, v/v); pH was adjusted to 2.5 with H$_3$PO$_4$; 1 mL/min | AZORBAX SB C-18 (250 × 4.6 mm, 5 µm) | UV detector; 238 nm | Monacolin K (lactone) | [48] |
| HPLC (Waters 1525) | Acetonitrile:Water (55:45, v/v); pH was adjusted to 2.5 with H$_3$PO$_4$; 1 mL/min | ZORBAX SB C-18 (250 × 4.6 mm, 5 µm) | UV detector; 238 nm | Monacolin K (lactone) | [49] |
| HPLC (Waters) | Acetonitrile:0.1% H$_3$PO$_4$ (70:30, v/v); 1 mL/min; 25 °C | Reverse-phase (RP)-18 (250 × 4.6 mm, 5 µm) | diode-array and UV detector; 237 nm | Monacolin K (lactone) | [50] |
| HPLC (Varian) | Acetonitrile:Water:Methanol (5:3:1, v/v); 1 mL/min | Varian C18 (250 × 4.6 mm, 5 µm) | UV detector; 230 nm | Monacolin K (lactone) | [28] |
| HPLC | Acetonitrile:Water (72:28, v/v); 0.5 mL/min | Beckman Ultrasphere ODS column (150 × 4.6 mm) | UV detector; 238 nm | Monacolin K (lactone) | [51] |
| HPLC (Waters 2690 Alliance) | Acetonitrile (A):0.1% Trifluoroacetic acid (B); A was from 35 to 75% in 20 min and keeping 75% from 20 to 28 min; 1 mL/min; 30 °C | Waters Symmetry C18 (150 × 3.9 mm, 5 µm) | 996 PDA detector; 237 nm | Monacolin K, J and L (their lactone and acid) | [52] |
| HPLC (Agilent 1260) | 0.1% Trifluoroacetic acid (A):Acetonitrile (B); in 20 min from 40% B to 75% B, 10 min 75% B, from 75 to 100% B in 5 min, 3 min at 100% B, from 100 to 40% B in 2 min and 5 min 40% B; 1 mL/min; 20 °C | RP-C18 (250 × 4.6 mm, 5 µm) | DAD detector; 237 nm | Monacolin K (acid and lactone) | [53] |
| HPLC (Dionex ultimate 3000) | Acetonitrile:50 mM KH$_2$PO$_4$, pH 3.5 (60:35, v/v); 1.5 mL/min; 40 °C | Dionex octadecyl silyl silica gel column (250 × 4.6 mm, 5 µm) | PAD (Ultimate 3000) detector; 237 nm | Monacolin K (acid and lactone) | [54] |
| Statin Window HPLC | Methanol (A):0.1% Phosphorus acid (B); Linear gradient elution from 60 to 90% of solvent A in 32 min and kept at 90% of solvent A for 3 min; 1 mL/min | - | UV detector; 237 nm | Monacolin K and L | [55] |
| HPCE (ACS 2000) | 30-80 mM Gly-NaOH buffer (pH 10.5) containing 16% (v/v) ethanol; 16 kV; 22 °C | fused-silica capillary (51 cm × 75 µm) | UV-vis detector; 238 nm | Monacolin K (acid) | [56] |
| MISPE-SIA-UV | Ammonium acetate buffer (pH 4.0):Acetonitrile (90:10, v/v) | miniaturized column (5.0 × 2.5 mm) | UV detector; 240 nm | Monacolin K (lactone) | [57] |
| Detection Methods                  | Mobile Phase                                                                 | Column                  | Detector                  | Detection Index       | Ref.  |
|-----------------------------------|------------------------------------------------------------------------------|-------------------------|---------------------------|-----------------------|-------|
| QCM nanosensor                    | Trichloroacetic acid (diluted with glycine–sodium hydroxide buffer at PH 10); 1 mL/min | -                       | QCM chip with lovastatin imprinted polymer | Monacolin K (lactone) | [58]  |
| Voltammetric (Metrohm)            | Frequency, 200 Hz; potential step, 2 mV; amplitude, 25 mV by applying a negative-going potential scan from ~0.6 to ~1.6 V; 22 °C | -                       | Auto-lab potentiostat     | Monacolin K (lactone) | [59]  |
| LC–MS/MS (Agilent 6460)           | A4 mM of ammonium formate plus 0.05% formic acid in water                  | Intersil ODS-3 (150 × 2.1 mm, 3.5 µm) | ESI                       | Monacolin K (lactone) | [60]  |
| LC–MS (Agilent Model 1100 and MSD Esquire 3000*) | Acetonitrile (A):0.1% phosphoric acid (B); 35% to 75% of A for 30 min and kept at 75% of A for 5 min; 0.5 mL/min | Hypersil gold column (150 × 4.6 mm, 5 µm) | UV detector; 237 nm | Monacolin K and Dehydromonacolin K (their lactone and acid) | [61]  |
| GC–MS (Agilent 6890)              | Ultrapure helium; 1 mL/min; an initial temperature of 70 °C for 4 min, and increased by 2 °C/min 70 to 100 °C (held 2 min), Then, the temperature was varied from 100 to 200 °C at 5 °C/min (held 20 min) and increased to 280 °C (held 5 min) at 10 °C/min. | fused silica capillary column HP-5MS (30 m × 0.25 mm) | 5975 GC/MSD mass selective detector | Monacolin K (acid and lactone) | [62]  |
| HPLC-MS (Waters 2695 Alliance, Thermo Finnigan) | Acetonitrile (A):0.1% trifluoroacetic acid (B); Linear gradient elution from 35 to 75% of solvent A in 30 min and kept at 75% of solvent A for 5 min; 1 mL/min; 35 °C | Hypersil ODS (250 × 4 mm, 5 µm) | PDA detector; 237 nm | Monacolin K (lactone and acid) and M, etc. | [63]  |
| HPLC-MS (Agilent HP 1100 and MSD VL model) | Acetonitrile (A): 0.1% trifluoroacetic acid (B); Linear gradient elution from 35 to 75% of solvent A in 30 min and kept at 75% of solvent A for 5 min; 1 mL/min; 35 °C | Hypersil ODS (250 × 4 mm, 5 µm) | PDA detector; 237 nm | Monacolin K (lactone and acid) and M, etc. | [64]  |
| HPLC-MS (Waters 2695 Alliance)    | Acetonitrile (A):0.1% trifluoroacetic acid (B); A was from 5 to 75% in 15 min, kept at 75% for 5 min, increased to 95%, then reduced to 5% in another 10 min | Waters Symmetry C18 (150 × 3.9 mm, 5 µm) and arrow-bore reversed-phase Zorbax SB-C18 (100 × 2.1 mm, 5 µm) | ESI; 2996 PDA detector; UV spectrum; 232, 239, 248 nm | Monacolin K (lactone and acid) | [65]  |
| HPLC-MS (Hitachi, Japan)          | Acetonitrile:0.2% Formic acid (70:30, v/v); 1 mL/min | Bisil ODS column (150 × 4.6 mm, 5 µm) | ESI MRM mode; 238 nm | Monacolin K (lactone and acid) | [66]  |
| HPLC-MS (Waters 510)              | Acetonitrile:Water (77:23, v/v, pH 3.0);0.8 mL/min; room temperature | Waters Symmetry C18 (250 × 4.6 mm, 5 µm) | UV200 detector | Monacolin K (lactone; acid and its methyl ester) | [67]  |
| HPLC-MS/MS (Thermo Fisher Scientific) | 0.1% HCOOH (A):CHCN (B); 80% A form 0 to 1.0 min, 10% A from 1 to 6.0 min, 10% A from 6 to 7.5 min, 80% A from 7.5 to 8 min; 0.25 mL/min | RP-C18 (20 × 2.1 mm, 3 µm) | ESI detector | Monacolin K (lactone and acid) | [68]  |
Table 2. Cont.

| Detection Methods | Detection Conditions | Detection Index | Ref. |
|-------------------|----------------------|-----------------|------|
| MISPE-UHPLC–MS/MS (Waters) | 0.5 mM Ammonium acetate (A, pH 4.0); Acetonitrile (B); B was from 30 to 70% over 3.7 min and decreasing 30% in 4.0 min; 0.35 mL/min; 40 °C | analytical column BEH C18 (50 × 2.1 mm, 1.7 μm) | ESI detector | Monacolin K (acid and lactone) [69] |
| LC/DAD/FLD/MS* (Agilent Series 1100) | Acetonitrile:water:formic acid (10:90:0.1, A); Acetonitrile:water:formic acid (90:10:0.05, B); 40–70% B (0–7 min) and 70–90% B (7–10 min); 1 mL/min; 25.0 ± 0.1 °C | Zorbax SB-C18 (250 × 4.6 mm, 5 μm) | ESI, UV (237 nm) fluorimetric (331, 500 nm) | Monacolin K M, L, and citrinin, etc. [70] |
| UHPLC–DAD–QToF-MS | 0.1% Formic acid (A); Acetonitrile with 0.1% formic acid (B); 65% A–35% A in 15 min and in next 3 min to 100% B; 0.35 mL/min; 35 °C | Agilent Zorbax SB-C18 RRHD (150 × 2.1 mm, 1.8 μm) | UV, 237 nm; ESI + ve mode | Monacolin K, J, and citrinin, etc. [71] |
| HPLC-Chip-QTOF-MS (Agilent 1260 capillary C, Agilent 6520) | 0.1% (v/v) Formic acid (A); Acetonitrile containing 0.1% (v/v) Formic acid (B) 0–2 min, 20% B; 2–10 min, 20–25% B; 10–22 min, 25–30% B; 22–30 min, 30–35% B; 30–36 min, 35–45% B; 36–53 min, 45–60% B; 53–60 min, 60–70% B; 60–85 min, 70–90% B; 85–90 min, 90% B; 1 mL/min; 25 °C | Zorbax 8SB-C18 bonded stationary phase (150 × 4.6 mm, 5 μm) | MS/MS detection (the collision energy 120 was set at 25 eV) | Monacolin K (acid and lactone), O, Q, and M, etc. [38] |
| UHPLC–DAD–QToF-MS(Agilent) | 0.1% Formic acid/water solution (1/1000, A); Formic acid/acetonitrile solution (1/1000, B); 0–3 min, 53% B; 3–5 min, 53–70% B; and 5–6 min, 70% B; 0.7 mL/min; 30 °C | Agilent Zorbax SB C18 (150 × 2.1 mm, 1.8 μm) | DAD-Q/TOF-MS detector; 237 nm | Total monacolins [72] |
| UPLC-QTOF-MS/MS | - | HSS C18 column (150 × 2.1 mm, 1.8 μm) | ESI | Monacolin K (lactone and acid) [73] |
| 400 MHz ¹H-NMR | 370 µL of distilled water and 60 µL of pH 7.4 NMR buffer (1.5 M KH₂PO₄ in D₂O, 0.1%; 3-(trimethylsilyl)-propionate acid-d₄ (TSP), 5 mM NaN₃) | 5-mm SEI probe | Ultrashield spectrometer (300.0 K.) | Total monacolins [74] |
In HPLC analysis, the separation and detection of species of several elements in a single analytical run can be accomplished. In order to make HPLC analysis simpler and more efficient, it is often coupled with UV and DAD detectors. For research into RYR products, HPLC is a common detection method and most laboratories and manufacturers can satisfy this condition [75]. As can be seen from the data in Table 2, the detection method of monacolins in RYR is mostly HPLC and the detection index of RYR is mostly monacolin K lactone. For monacolin K acid and other monacolins, acetonitrile: 0.1% trifluoroacetic acid, acetonitrile: 50 mM potassium hydrogen phosphate and methanol: 0.1% aqueous phosphoric acid were used as the mobile phase. Tsukahara [47] used methanol: 0.1% aqueous phosphoric acid (72:28, v/v) as the mobile phase, isocratic elution for 25 min, and linear elution with 100% methanol until 30 min, respectively. The contents of monacolin K (lactone) and citrinin were detected; Monascus sp. with a deep red color, high monacolin K production, and no citrinin was screened. Although there are many HPLC methods, the measurement conditions such as a mobile phase, separation column, and detector are different for each research purpose, resulting in different detectable components. Zhang et al. [48,49] developed a new SSF process using agar as a carrier and then optimized the grain for the highest yield of monacolin K by SSF with determination of monacolin K by HPLC, and the effects of fermentation substrate, fermentation temperature, and time on the yield of monacolin K were investigated. Liu et al. [50] used HPLC-UV to optimize the extraction conditions of monacolin K in functional RYR.

MISPE is a solid-phase extraction technique based on molecular imprinting which is often combined with HPLC and HPLC-MS/MS. It can significantly improve the extraction rate and purity of monacolin K in RYR, and reduce the impurity of the components to be tested. The matrix effects on the analysis results can be removed, and the subsequent analysis of monacolin K was more efficient and faster. Eren et al. [58] developed a sensitive molecular imprinted quartz crystal microbalance (QCM) sensor for the selective determination of monacolin K lactone in RYR.

GC-MS/MS and HPLC-MS/MS are joint detection techniques. In the actual analysis, HPLC-MS/MS is more commonly used. The tandem mass spectrometry technology has higher resolution and a faster analysis speed. It offers good detection of monacolin analogs in RYR. Donna et al. [68] uses the multiple reaction monitoring (MRM) mode and HPLC-MS/MS as the analytical method: simvastatin and pravastatin were used as indicators to determine the acid and lactone monacolin K content in RYR. Different detectors have different detection ranges. Svoboda et al. [69] connected solid-phase extraction of molecularly imprinted polymers, developing a UHPLC-MS method without a matrix effect. Mornar et al. [70] connected diode arrays, fluorescence, and mass spectrometry detectors to simultaneously measure monacolin K, L, M, monacolin K hydroxy acid, dehydromonacolin K, and citrinin in RYR products.

In addition, Nigovic et al. [59] developed a simple and fast voltammetric method to detect the content of lactone monacolin K in RYR, and used micellar electrokinetic capillary chromatography to detect the two configurations of monacolin K in red yeast preparations [76].

3. The Standards of Quality Control for RYR

Due to the lack of scientific data, RYR has not been officially registered by the FDA [77]. Therefore, RYR is often used as a food or as a dietary supplement abroad. Taiwan promulgated the Hongqu Health Food Standard in 2007 (Taiwan Guardian Food No. 0960406448). Regarding the red blood safety index, the national standard for the detection of citrinin is “Determination of citrinin in RYR products (GB T5009. 222-2008).” The European Food Safety Authority is currently reassessing the safety of a 10-mg dose of monacolin K as a food supplement [78].

In addition, according to a literature search, only the British Pharmacopoeia provides the functional RYR standard abroad. Most of the standards are the laws of various provinces and cities in China. In China, monacolin K is the lipid-lowering component in functional RYR, so the pharmacopoeia, ministerial standards, and regional standards evaluate the quality of functional RYR based on the content of monacolin K lactone. The current standards are listed in Table 3.
| Standard | Type | Detection Methods | Indicator Component | Regulation | Ref. |
|----------|------|-------------------|---------------------|------------|-----|
| Martindale Pharmacopoeia | Hongqu | No request | No request | No request | [79] |
| Chinese Pharmacopoeia 2015 | Chinese Herbal Medicine (Hongqu) | HPLC (Cosmosil 5C18-MS-II, 26 cm × 4.6 mm, 5 µm, Methanol:Water (75:25, v/v), UV detector 237 nm) | Monacolin K (lactone) | ≥0.22% | [80] |
| | Chinese patent medicine (Xuezhikang) | HPLC (Cosmosil 5C18-MS-II, 26 cm × 4.6 mm, 5 µm, Methanol:Water (75:25, v/v), UV detector 237 nm) | Monacolin K (lactone) | Not less than 2.5 mg per capsule | |
| Functional red yeast rice QB/T 2847-2007 | Functional food | RP-HPLC (C18, 250 mm × 4.6 mm, Methanol:Water: Phosphoric acid (385:115:0.14, v/v), UV detector 238 nm) | Monacolin K (lactone and acid) | The sum of monacolin K lactone and acid ≥0.40% | [81] |
| The standard of Chinese herbal medicine of Yunnan province (2005) | Chinese Herbal Medicine (Hongqu) | HPLC (Cosmosil 5C18-MS-II, Acetonitrile-Methanol-0.1% Phosphoric acid (60:5:35, v/v), UV detector 238 nm) | Monacolin K (lactone) | ≥0.40% | [82] |
| The standard of Chinese herbal medicine of Fujian province (2009) | Chinese Herbal Medicine (Hongqu) | No request | No request | No request | [83] |
| The standard of Chinese herbal medicine of Henan province (1991) | Chinese Herbal Medicine (Hongqu) | No request | No request | No request | [84] |
| The standard of Chinese herbal medicine of Hubei province (2009) | Chinese Herbal Medicine (Hongqu) | No request | No request | No request | [85] |
| The standard of Chinese herbal medicine of Beijing (1998) | Chinese Herbal Medicine (Hongqu) | No request | No request | No request | [86] |
| The standard of Chinese herbal medicine of Shandong Province (2012) | Chinese Medicine Yinpian (Hongqu Mi) | No request | No request | No request | [87] |
Table 3. Cont.

| Standard                                                                 | Type                          | Detection Methods                                                                 | Indicator Component                  | Regulation                                                                 | Ref. |
|-------------------------------------------------------------------------|-------------------------------|-----------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------|------|
| Standard for Chinese Medicine Yinpian Processing of Sichuan Province (2015) | Chinese Medicine Yinpian (Hongqu) | HPLC (Cosmosil 5C18-MS-II, Acetonitrile-Methanol-0.1% Phosphoric acid (55:5:40, v/v), UV detector 238 nm) | Monacolin K (lactone)                | ≥0.40%                                                                    | [88] |
| Standard for Chinese Medicine Yinpian Processing of Zhejiang Province (2015) | Chinese Medicine Yinpian (Hongqu) | HPLC (Cosmosil 5C18-MS-II, Acetonitrile-Methanol-0.1% Phosphoric acid (55:5:40, v/v), UV detector 238 nm) | Monacolin K (lactone and acid)      | Total ≥ 0.30%; The peak area of acid monacolin K is not less than 5% of the lactone monacolin K peak area | [89] |
| Standard for Chinese Medicine Yinpian Processing of Hunan Province (2010) | Chinese Medicine Yinpian (Hongqu) | No request                                                                       | No request                           | No request                                                                | [90] |
| Standard for Chinese Medicine Yinpian Processing of Heilongjiang Province (2012) | Chinese Medicine Yinpian (Hongqu) | No request                                                                       | No request                           | No request                                                                | [91] |
| Standard for Chinese Medicine Yinpian Processing of Hebei Province (2003) | Chinese Medicine Yinpian (Hongqu) | No request                                                                       | No request                           | No request                                                                | [92] |
| Standard for Chinese Medicine Yinpian Processing of Beijing (2008)       | Chinese Medicine Yinpian (Hongqu) | No request                                                                       | No request                           | No request                                                                | [93] |
| Standard for Chinese Medicine Yinpian Processing of Chongqing (2008)      | Chinese Medicine Yinpian (Hongqu) | No request                                                                       | No request                           | No request                                                                | [94] |
| Standard for Chinese Medicine Yinpian Processing of Shanghai Province (2008) | Chinese Medicine Yinpian (Hongqu) | No request                                                                       | No request                           | No request                                                                | [95] |
| Standard for Chinese Medicine Yinpian Processing of Shandong Province (2012) | Chinese Medicine Yinpian (Hongqu Mi) | No request                                                                       | No request                           | No request                                                                | [96] |
Table 3. Cont.

| Standard                                                                 | Type                               | Detection Methods | Indicator Component | Regulation | Ref. |
|--------------------------------------------------------------------------|------------------------------------|-------------------|---------------------|------------|------|
| Standard for Chinese Medicine Yinpian Processing of Henan Province (2005) | Chinese Medicine Yinpian (Hongqu Mi) | No request        | No request          | No request | [97] |
| Standard for Chinese Medicine Yinpian Processing of Tianjin (2018)       | Chinese Medicine Yinpian (Hongqu Mi) | No request        | No request          | No request | [98] |
| Standard for Chinese Medicine Yinpian Processing of Fujian Province (2012) | Chinese Medicine Yinpian (Hongqu Mi) | No request        | No request          | No request | [99] |
According to Table 3, most standards have no clear requirement for inspection of the content of monacolin K of RYR; some of the above criteria clarify the required content of monacolin K lactone in RYR (generally not less than 0.40%), while just a few standards mentioned the content requirements of monacolin K lactone and acid. In Table 3, only five standards have been specified for the determination of monacolin K in functional RYR. In the *Chinese Pharmacopoeia* (2015), monacolin K lactone is the only index of quality control of functional RYR and the limit of minimum content of monacolin K lactone is 0.22%. “The standard of Chinese herbal medicine of Yunnan Province (2005)” and “Standard for Chinese Medicine Yinpian Processing of Sichuan Province (2015)” also required that monacolin K lactone should serve as the quality control of functional RYR and the lowest content is 0.40%. However, there are two standards that indicate requirements for the acid structure. In the industrial standard “Functional red yeast rice QB/T 2847–2007,” it is regulated that the sum of monacolin K lactone and acid in functional RYR should be not less than 0.40%. The “Standard for Chinese Medicine Yinpian Processing of Zhejiang Province (2015)” required that in functional RYR, the sum of monacolin K lactone and acid must be more than 0.30% and the peak area of acid monacolin K must not be less than 5% of the lactone monacolin K peak area. In addition to the above criteria, the other standards listed in Table 3 do not mention the quality control components and content limits of functional RYR.

*Monascus* can produce harmful secondary metabolites during the fermentation process, such as citrinin, which is a highly toxic, mutagenic, and carcinogenic metabolite and has been implicated as a causative agent in human hepatic and extrahepatic carcinogenesis [21]. It causes serious health problems such as liver and kidney disease, nervous system damage, and carcinogenicity. In addition, aflatoxin may be generated, caused by bacterial contamination in the fermentation process, for a variety of reasons. Aflatoxins are potent carcinogens that affect all organ systems, particularly the liver and kidneys, and are also genotoxic and may cause birth defects in children. They can cause immunosuppression and may reduce resistance to infectious agents such as HIV and tuberculosis. The ingestion of citrinin and aflatoxins is harmful to humans and animals. Therefore, it is necessary to carry out a safety check on the RYR. There are three standards that require security checks. For the determination of citrinin, “Standard for Chinese Medicine Yinpian Processing of Sichuan Province (2015)” and “Functional red yeast rice QB/T 2847-2007” use the HPLC method; detection is by a fluorescence detector with excitation wavelength $\lambda_{\text{ex}} = 331$ nm, emission wavelength $\lambda_{\text{em}} = 500$ nm. The two standards decree that the content of citrinin should not exceed 50 µg/kg. The “Food additives Red yeast rice GB1886.19-2015” and “Standard for Chinese Medicine Yinpian Processing of Sichuan Province (2015)” utilize two methods to detect the content of aflatoxins. One is HPLC with a fluorescence detector ($\lambda_{\text{ex}} = 360$ or $365$ nm, $\lambda_{\text{em}} = 450$ nm). The other is HPLC-MS with ESI, in positive ion mode, with triple quadrupole tandem mass spectrometry as the detector. The two standards require that the content of aflatoxin B1 not exceed 5 µg/kg.

### 4. The Authentication Methods of Functional RYR

Functional RYR has a large market as a lipid-lowering drug, with the indicator ingredients being monacolin K. Because the structure of monacolin K in RYR is naturally the same as that of commercial lovastatin [12], it is not possible to distinguish commercial lovastatin from monacolin K with the currently used detection methods, such as HPLC, HPLC-MS/MS, and GC-MS. Some researchers [100,101] have found that commercial lovastatin is added to common RYR to impersonate functional RYR and gain illegal profits in the pharmaceutical market. Therefore, it is necessary to find a reasonable and effective method for authenticating functional RYR as quickly as possible. There are a few reports of a method for authenticating functional RYR, shown in Table 4.
Table 4. The authentication methods of functional RYR.

| Detection Methods          | Detection Conditions                                                                 | Detection Index     | Ref.       |
|----------------------------|--------------------------------------------------------------------------------------|---------------------|------------|
| UHPLC–QQQ-MS,              | ACQUITY UHPLC BEH C18 (100 mm × 2.1 mm, 1.7 μm); A: 0.1% formic acid in water; B: 0.1% formic acid in acetonitrile; 0–12 min, 20–80% B; 12–14 min, 80–100% B; 14–16 min, 100% B; 0.35 mL/min; 40 °C; Q-TOF-MS detector | heptaketide         | [8]        |
| UHPLC-Q-TOF-MS             |                                                                                      |                     |            |
| HPLC                      | Spherisorb ODS-2 column (250 × 0.4 mm, 0.5 μm + precolumn Zorbax Reliance Cartridge), A = 0.2% phosphoric acid in water; B = acetonitrile. Gradient: A/B 65/35 to 25/75 in 20 min; A/B 25/75 to 25/75 in 28 min; 1 mL/min; DAD detector, 237 nm | Monacolin K lactone and acid, other monacolins | [100]      |
| Stable isotope ratio analysis. (13C-NMR) | The 13C/12C ratio was measured (around 0.5 mg) using total combustion in an elemental analyzer; MS detector | 13C/12C ratio      | [101]      |

Zhu et al. [8] extracted decalins from different types of RYR, including four batches of common RYR, two batches of functional RYR, and three functional RYR formulas (Xuehizikang capsule, Hongqu Xiaohisu, and Zhibituo tablets), and simultaneously determined their levels by UHPLC–QQQ-MS and UHPLC-Q-TOF-MS. The chromatography was performed on an ACQUITY UHPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm), with formic acid and acetonitrile as the mobile phase with gradient elution, a flow rate of 0.35 mL/min, and a column temperature of 40 °C. The results of UHPLC–QQQ-MS analyses showed that the individual or total decalin contents in the raw material of functional RYR are much higher than their preparations. However, no decalin was detected in the common red yeast rice. The data demonstrated that decalins exist in functional RYR but not in common RYR. Moreover, based on the quantitative results of decalins in RYR, heptaketide was proposed to be another marker for the quality control of functional RYR. Their study demonstrated that the UHPLC-Q-TOF-MS and UHPLC–QQQ-MS methods described in their paper are powerful and reliable tools for the quality control of RYR.

Nannoni et al. [100] found that monacolin K and monacolin K acid form (MK and MKA are considered to be the active monacolins) have a proportional relationship in all secondary monacolins, which can be used to determine whether commercial lovastatin was added to RYR. The instrument conditions: Spherisorb ODS-2 column (250 × 0.4 mm, 0.5 μm + precolumn Zorbax Reliance Cartridge), DAD detector at 237 nm, phosphoric acid and acetonitrile as the mobile phase with gradient elution; the flow rate is 1 mL/min. When analyzing the data, it was found that there was a scaling relationship between MK and MKA and the sum of the total secondary monacolins. Two discriminant equations had been proposed as follows. If the proportional relationship of RYR products did not meet the two discriminants as mentioned, the product is determined to be adulterated; if only Equation (1) did not accord, it proves that it is likely adulterated; if only the Equation (2) did not accord, it proves that it is possibly adulterated. MK and MKA tend to transform each other, and the content of MK is dominant, but does not exceed 70% of the total of the two monacolins. Therefore, if the MK content is higher in the HPLC analysis, it is proven that the product is likely adulterated. In 32 samples’ data, 16 did not meet the formula, which indicated that the 16 samples were likely to be adulterated.

\[
\frac{\text{other secondary monacolins}}{\text{MK + MKA}} > 0.02 \quad (1)
\]
\[
\frac{\text{MKA}}{\text{MK + MKA}} > 0.30 \quad (2)
\]

Perini et al. [101] utilized the analysis of δ2H and δ13C with Isotope Ratio Mass Spectrometry to distinguish monacolin K in functional RYR and commercial lovastatin. The fermentation matrix of SSF and SmF of RYR is different. Commercial lovastatin is produced by SmF using an Aspergillus
terreus mutant, which decreases the production costs. In general, sufficient nutrients such as glucose, oat flour, corn steep liquor, polyethylene glycol, and trace elements are administered on the culture medium, and different substrates including glucose, lactose, corn, etc. are used as the media of SmF. SSF mainly uses cereals like millet as a fermentation substrate for the production of MK in functional RYR. In 1H-NMR analysis, the δ2H values of 15 commercial lovastatin and three drugs with lovastatin ranged from −207.7‰ to −265.5‰; 18 monacolin K from functional RYR ranged from −245.6‰ to −269.2‰. In 13C-NMR analysis, the δ13C values of 15 commercial lovastatin and three drugs with lovastatin ranged from −21.4‰ to −261.4‰; 18 monacolin K from functional RYR ranged from −30.7‰ to −28.2‰. The results showed that 1H-NMR cannot identify the authenticity of functional RYR, but 13C-NMR can. The δ2H values in samples are mainly derived from water, and, due to different water sources in different regions, the δ2H values are different. The δ13C values of MK extracted from functional RYR and commercial lovastatin have a completely different δ13C range because of the different matrices. These phenomena are consistent with the biological sources in the matrix; the rice has a C3 photosynthesis cycle with a δ13C value between −27‰ and −25‰. The plant photosynthesis cycle of C4 is in the range of −10‰ to −16‰, which is consistent with the determination of lovastatin [102]. Moreover, MK would not undergo isotope fractionation during extraction. All of the above demonstrated that the analysis of δ13C with isotope ratio mass spectrometry can authenticate functional RYR.

5. Future Perspectives and Conclusions

Nowadays, increasing evidence has demonstrated that monomers/extracts derived from Traditional Chinese Medicines (TCM) are valuable resources for finding novel and effective candidate drugs with low toxicities [103,104]. RYR, a known TCM fermented by Monascus, could be used to stimulate blood circulation, the spleen, and digestion. Since monacolin K was first isolated from Monascus and determined by Endo to have a lipid-lowering effect, Monascus fermentation products have attracted much attention, and RYR is one of the most eye-catching products, divided into common RYR for food and functional RYR for medicine in the market.

Monacolin K (lactone and acid) is the main lipid-lowering component of functional RYR, and the acid form is the efficient form in the body. At present, many studies have shown that there are many other monacolins, including dihydromonacolin MV, monacophenyl, monacolin O and P, etc. in RYR, and some of them have similar effects to monacolin K.

Since the structure and biosynthetic pathway of monacolin K are similar to that of commercial lovastatin, it is hard to differentiate the two using common detection methods, such as HPLC, HPLC-MS/MS, and GC-MS. Therefore, some researchers have reported that commercial lovastatin is added to common RYR to imitate functional RYR, satisfying the quality standard requirements of functional RYR and thus achieving illegal profitability. This has had a negative impact on the RYR market. In response to this phenomenon, there are a few studies that have shown that some suitable methods can be used to authenticate functional RYR. Although there are currently three methods for identifying functional RYR, in order to better identify functional RYR, researchers should conduct more in-depth research and establish a practical, accurate, fast, and stable authentication method.

The composition of TCM is complex, and how to control the quality of TCM is becoming a hot topic. The quality evaluation of TCM is the basis for ensuring the effectiveness and safety of TCM. Due to a variety of factors, the functional RYR quality would be affected, so a dependent quality control system needs to be established to ensure the highest degree of safety and effectiveness for functional RYR products [105]. For solving this problem, more complete quality control standards of TCM should be established.

5.1. The Spectrum-Effect of TCM

The spectrum-effect of TCM, due to its comprehensive and quantifiable advantages, has been widely used in the quality control of single-flavor and Chinese medicine formulas in recent years [106].
The spectrum-effect study of TCM aims to establish a link between the fingerprint and the actual efficacy; according to the results of pharmacological experiments, the chromatographic peaks related to the efficacy of the drug are found and structurally confirmed, so as to clarify the basis of the pharmacodynamic substance. This achieves the purpose of controlling the quality of TCM [107]. Shi et al. [108], using UPLC-MS² analysis, identified the psoralen ethanol extract and determined the tyrosinase activity by the oxidative rate method of levodopa, evaluating its inhibition and the activation of tyrosinase. Based on the anti-inflammatory and analgesic activity of *Alpinia zerumbet*, Xiao et al. [109] established the fingerprint of *Alpinia zerumbet* volatile oil and simultaneously evaluated the anti-inflammatory and analgesic effects of *Alpinia zerumbet* volatile oil by pharmacological experiments. After spectral-effect correlation assessment, the main bioactive components of analgesic and anti-inflammatory activities may be α-furan, β-pinene, camphor, and α-cadino. The lipid-lowering components of functional RYR include monacolin K, J, L, M, X, and their acid forms, etc., but the current standards either have no indicator components or only determined monacolin K; therefore, in order to truly reflect the quality of functional RYR, according to the spectral pharmacodynamics, drug supervision and administration departments should establish characteristic fingerprints of functional RYR to better evaluate its quality.

5.2. The TCM Quality Traceability System Based On the Quality Marker

The TCM quality traceability system of functional RYR should be established based on the “quality marker” (Q-marker) [110]. The TCM quality traceability system uses Internet of Things and block chain technology, cloud computing, big data, and other information technologies to process the key information of TCM from planting, processing, production, and circulation to use, and then to ensure that sources of TCM can be known and traced, its quality can be checked, and responsibility can be investigated [111,112]. Q-marker is a complex system for quality assessment and production process control of TCM products with traceability. Q-marker reflects the compatibility of TCM and modern pharmacological study; the drug effect (such as effectiveness and safety) should be demonstrated to be associated with the identified quality marker [113]. Sheng [114] designed an electronic products code (EPC) of quality traceability for Bobaishao Decoction pieces based on a radio frequency identification (RFID) tag, and applied it to the quality traceability Internet of Things system of Bobaishao Decoction pieces. Zhou et al. [115] determined that the quality markers for *Bulbus fritillariae* were 28 compounds such as solanidine, zhebeiresinol, puqiedine, etc. by using UPLC-Q/TOF-MS combined with principal component analysis (PCA), an artificial neural network (ANN), and biological evaluation. The TCM quality traceability system based on the Q-marker has received more and more attention in the quality control of TCM. However, the formal establishment of this system requires a lot of related research, such as Q-marker selection methods (biopotency, biological fingerprinting, pharmacokinetics, etc.), design methods of traceability system, and processing of information technology such as block chain, cloud computing, big data, etc.

5.3. Improvement of Relevant Policies and Regulations of Functional RYR

With the deepening of the study of functional RYR, it is found that monacolins play a synergistic role in the lipid-lowering effect of functional RYR [24]. However, the current standards use monacolin K as the sole indicator of quality control of functional RYR. Therefore, the quality of the RYR products cannot be truly reflected by the current standards.

Based on existing detection methods, in order to reflect the quality of the functional RYR, the content and ratio of acid and lactone monacolin K should be determined synchronously. Then we can gradually establish better quality control methods, such as characteristic fingerprints based on spectrum-effect research. In addition, the quality control of drugs is inseparable from the help of government departments. Relevant departments should strengthen the supervision of the RYR market, strictly control the application approval of RYR producers, stipulate the fermentation process of different types of RYR, including the production conditions such as strains, fermented grains, fermentation time, etc., and check the functional RYR on the market for quality. For comprehensively
evaluating the quality of functional RYR, it is necessary to establish better quality standards with a strong policy-oriented nature; at the same time, policy regulations are required to crack down on illegal substitutions.

**Author Contributions:** Conceptualization, C.W. and X.L.; writing—original draft preparation, J.S., J.L., Z.M., Q.S.; writing—review and editing, J.L. and C.W.; funding acquisition, C.W. and X.L.

**Funding:** This work was supported by National Natural Science Foundation of China (No. 81703706) and scientific research project of TCM industry (No. 201507004-03).

**Conflicts of Interest:** The authors declare that there is no conflict of interest.

**References**

1. Carels, M.; Shepherd, D. The effect of different nitrogen sources on pigment production and sporulation of *Monascus* species in submerged, shaken culture. *Can. J. Microbiol.* **1977**, *23*, 1360–1372. [CrossRef] [PubMed]

2. Ozlem, T.; Sebile, A. A review on the red yeast rice (*Monascus purpureus*). *Turk. Electron. J. Biotechnol.* **2004**, *2*, 37–49.

3. Chen, W.; He, Y.; Zhou, Y.; Shao, Y.; Feng, Y.; Li, M.; Chen, F. Edible Filamentous Fungi from the Species *Monascus*: Early Traditional Fermentations, Modern Molecular Biology, and Future Genomics. *Compr. Rev. Food Sci. Food Saf.* **2015**, *14*, 555–567. [CrossRef]

4. Lin, F. Textual research on Gutian as place where red yeast rice originated. *Chin. Tradit. Herb. Drugs* **2017**, *48*, 2793–2800.

5. Rojsuntornkitti, K.; Jittrepotch, N.; Kongbangkerd, T.; Kraboun, K. Substitution of nitrite by Chinese red broken rice powder in Thai traditional fermented pork sausage (Nham). *Int. Food Res. J.* **2010**, *17*, 153–161.

6. Kohama, Y.; Matsumoto, S.; Mimura, T.; Tanabe, N.; Inada, A.; Nakanishi, T. Isolation and identification of hypotensive principles in red-mold rice. *Chem. Pharm. Bull.* **1987**, *35*, 2484–2489. [CrossRef] [PubMed]

7. Endo, A. Monacolin K, A new hypocholesterolemic agent produced by a *Monascus* Species. *J. Antibiot.* **1979**, *32*, 852–856. [CrossRef]

8. Zhu, L.; Han, Q.-B.; Ho, A.; Hsiao, W.-L.; Jiang, Z.-H. Characterization and simultaneous determination of immunosuppressive decalins in red yeast rice by ultra-high-performance liquid chromatography hyphenated with mass spectrometry. *J. Chromatogr. A* **2013**, *1303*, 54–61. [CrossRef]

9. State Bureau of Technical Supervision. *The State Standard of the People’s Republic of China: Food Additives Red Yeast Rice GB1886.19-2015*; China Light Industry Press: Beijing, China, 2015; p. 3.

10. Chen, C.H.; Yang, J.C.; Uang, Y.S.; Lin, C.J. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. *Int. J. Pharm.* **2013**, *444*, 18–24. [CrossRef]

11. Xue, Y.; Tao, L.; Wu, S.; Wang, G.; Qian, L.; Li, J.; Liao, L.; Tang, J.; Ji, K. Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: A single center randomized pilot trial. *BMC Cardiovasc. Disord.* **2017**, *17*, 1–7. [CrossRef]

12. Liu, J.; Zhang, K.; Shi, Y.; Grimsgaard, S.; Alraek, T.; Fonnebo, V. Chinese red yeast rice (*Monascus purpureus*) for primary hyperlipidemia: A meta-analysis of randomized controlled trials. *Chin. Med.* **2006**, *1*, 4. [CrossRef] [PubMed]

13. Lu, Z.; Kou, W.; Du, B.; Wu, Y.; Zhao, S.; Brusco, O.A.; Morgan, J.M.; Capuzzi, D.M. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. *Am. J. Cardiol.* **2008**, *101*, 1689–1693. [CrossRef] [PubMed]

14. Moriarty, P.M.; Roth, E.M.; Karsns, A.; Ye, P.; Zhao, S.-P.; Liao, Y.; Li, S. Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study. *J. Clin. Lipidol.* **2014**, *8*, 568–575. [CrossRef] [PubMed]

15. Zhang, Z.; Ali, Z.; Babahana, I.; Ikhlas, K.; Khan, A. Cytotoxic monacolins from red yeast rice, a Chinese medicine and food. *Food Chem.* **2016**, *202*, 262–268. [CrossRef]

16. Wu, H.C.; Cheng, M.J.; Wu, M.D.; Chen, J.J.; Chen, Y.L.; Chang, H.S.; Chen, K.P. Secondary metabolites from the fermented rice of the fungus *Monascus purpureus* and their bioactivities. *Nat. Prod. Res.* **2018**, *1*, 1–10. [CrossRef] [PubMed]

17. Thu, N.; Mitchell, K.; Antonello, S. Red Yeast Rice. *Foods* **2017**, *6*, 19. [CrossRef]
18. Choe, D.; Lee, J.; Woo, S.; Shin, C.S. Evaluation of the amine derivatives of *Monascus* pigment with anti-obesity activities. *Food Chem.* 2012, 134, 315–323. [CrossRef]
19. Liu, S.F.; Wang, Y.R.; Shen, Y.C.; Chen, C.L.; Huang, C.N.; Pan, T.M.; Wang, C.K. A randomized, double-blind clinical study of the effects of Ankascin 568 plus on blood lipid regulation. *J. Food Drug Anal.* 2018, 26, 393–400. [CrossRef]
20. Hsu, W.H.; Chen, T.H.; Lee, B.H.; Hsu, Y.W.; Pan, T.M. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice. *Food Chem. Toxicol.* 2014, 64, 94–103. [CrossRef]
21. Atar, N.; Eren, T.; Yola, M.L. A molecular imprinted SPR biosensor for sensitive determination of citrinin in red yeast rice. *Food Chem.* 2015, 184, 7–11. [CrossRef]
22. Mazza, A.; Lenti, S.; Schiavon, L.; Di Giacomo, E.; Tomasi, M.; Manunta, R.; Rubello, D. Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. *Biomed. Pharmacother.* 2018, 105, 992–996. [CrossRef]
23. Akira, E. A historical perspective on the discovery of statins. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 2010, 86, 484–493.
24. Musselman, M.E.; Pettit, R.S.; Derenski, K.L. A review and update of red yeast rice. *J. Evid. Based Complement. Alternat Med.* 2012, 17, 33–39. [CrossRef]
25. Akira, E. Drugs inhibiting HMG-CoA reductase. *Pharmac. Ther.* 2012, 134, 33–39. [CrossRef]
26. Seenivasan, A.; Subhagar, S.; Aravindan, R.; Viruthagiri, T. Microbial production and biomedical applications of lovastatin. *Indian J. Pharm. Sci.* 2008, 70, 701–709.
27. Alberts, A.W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Springer, J. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. *Proc. Natl. Acad. Sci. USA* 1980, 77, 3957–3961. [CrossRef]
28. Leone, G.; Consuni, M.; Pepi, S.; Lamponi, S.; Bonechi, C.; Tamasi, G.; Magnani, A. New formulations to enhance lovastatin release from red yeast rice (RYR). *J. Drug Deliv. Sci. Technol.* 2016, 36, 110–119. [CrossRef]
29. Endo, A.; Hasumi, K.; Nakamura, T.; Kunitshima, M.; Masuda, M. Dihydromonacolin L and monacolin X, new metabolites that inhibit cholesterol biosynthesis. *J. Antibiot.* 1985, 38, 321–327. [CrossRef]
30. Endo, A.; Hasumi, K.; Negishi, S. Monacolin J and L, new inhibitors of cholesterol biosynthesis produced by *Monascus ruber*. *J. Antibiot.* 1985, 38, 420–422. [CrossRef]
31. Endo, A.; Komagata, D.; Shimada, H. Monacolin M, A new inhibitor of cholesterol biosynthesis. *J. Antibiot.* 1986, 39, 1670–1673. [CrossRef]
32. Li, Y.G.; Zhang, F.; Wang, Z.T.; Hu, Z.B. Identification and chemical profiling of monacolins in red yeast rice using high performance liquid chromatography with photodiode array detector and mass spectrometry. *J. Pharm Biomed. Anal.* 2004, 35, 1101–1112. [CrossRef]
33. Dhale, M.A.; Divakar, S.; Kumar, S.U.; Vijayalakshmi, G. Isolation and characterization of dihydromonacolin-MV from *Monascus purpureus* for antioxidant properties. *Appl. Microbiol. Biotechnol.* 2006, 73, 1197–1202. [CrossRef]
34. Liu, M.T.; Li, J.J.; Shang, X.Y.; Li, S.; Li, L.L.; Luan, N.; Jin, Z.L. Structure elucidation and complete NMR spectral assignment of an unusual aromatic monacolin analog from *Monascus purpureus*. *Magn. Reson. Chem.* 2011, 49, 129–131. [CrossRef]
35. Liu, M.T.; Wang, A.L.; Sun, Z.; Li, J.J.; Wu, X.L.; Liu, Y.X.; Shang, X.Y. Cytotoxic monacolin analogs from *Monascus purpureus*-fermented rice. *J. Asian Nat. Prod. Res.* 2013, 15, 600–609. [CrossRef]
36. Zhu, L.; You, L.F.; Lu, J.G.; Zhu, G.Y.; Wang, J.R.; Han, Q.B.; Jiang, Z.H. Cytotoxic Dehydromonacolins from Red Yeast Rice. *J. Agric. Food Chem.* 2012, 60, 934–939. [CrossRef]
37. Zhang, B.; Liu, T.X.; Wang, A.L.; Li, J.J.; Wang, X.; Luan, N.; Ji, L.L.; Shang, X.Y. Four new monacolin analogs from *Monascus purpureus*-fermented rice. *J. Asian Nat. Prod. Res.* 2017, 209–216. [CrossRef]
38. Li, M.N.; Li, C.R.; Gao, W.; Li, P.; Yang, H. Highly sensitive strategy for identification of trace chemicals in complex matrix: Application to analysis of monacolin analogues in *monascus* fermented rice product. *Anal. Chem. Acta.* 2017, 982, 156–167. [CrossRef]
39. Chan, J.K.; Moore, R.N.; Nakashima, T.T.; Vederas, J.C. Biosynthesis of mevinolin. Special assignment by double-quantum coherence NMR after high carbon-13 incorporation. *J. Am. Chem. Soc.* 1983, 105, 3334–3336. [CrossRef]
40. Kimura, K.; Komagata, D.; Murakawa, S.; Endo, A. Biosynthesis of monacolins: Conversion of monacolin J to monacolin K (mevinolin). *J. Antibiot.* 1990, 43, 1621–1622. [CrossRef]
41. Akira, E. The origin of the statins. Int. Congr. Ser. 2004, 1262, 3–8.
42. Barrios-González, J.; Miranda, R.U. Biotechnological production and applications of statins. Appl. Microbiol. Biotechnol. 2010, 85, 869–883. [CrossRef]
43. Patel, S. Functional food red yeast rice (RYR) for metabolic syndrome amelioration: A review on pros and cons. World J. Microbiol. Biotechnol. 2016, 32. [CrossRef]
44. Patel, S.; Akhtar, N. Fungus Monascus-Fermented Red Yeast Rice (RYR): Natural Therapeutic Statin Source or Mycotoxin? Fungi. Role Sustain. Dev. Curr. Perspect. 2018, 739–752.
45. Singgh, M.; Saraswaty, V.; Ratnaisingrum, D.; Priatni, S.; Damayanti, S. The Influence of Temperature and Ethanol Concentration in Monacolin K Extraction from Monascus Fermented Rice. Procedia Chem. 2014, 9, 242–247. [CrossRef]
46. Asthana, S.; Kaur, V.; Chawla, P.; Saraf, S. Rapid and Sensitive HPLC-UV method for Simultaneous Estimation of Nifedipine, Nateglinide and Lovastatin: Quantitative Application to Polypill Based Synthetic Ternary Mixture. Int. J. Pharmtech. Res. 2010, 2, 682–688.
47. Tsukahara, M.; Shinzato, N.; Tamaki, Y.; Namihira, T.; Matsu, T. Red Yeast Rice Fermentation by Selected Monascus sp. with Deep-Red Color, Lovastatin Production but No Citrinin, and Effect of Temperature-Shift Cultivation on Lovastatin Production. Appl. Biochem. Biotechnol. 2009, 158, 476–482. [CrossRef]
48. Zhang, B.B.; Lu, L.P.; Xia, Y.; Wang, Y.L.; Xu, G.R. Use of agar as carrier in solid-state fermentation for Monacolin K production by Monascus: A novel method for direct determination of biomass and accurate comparison with submerged fermentation. Biochem. Eng. J. 2013, 80, 10–13. [CrossRef]
49. Zhang, B.B.; Xing, H.B.; Jiang, B.J.; Chen, L.; Xu, G.R.; Jiang, Y.; Zhang, D.Y. Using millet as substrate for efficient production of monacolin K by solid-state fermentation of Monascus ruber. J. Biosci. Bioeng. 2018, 125, 333–338. [CrossRef]
50. Liu, Y.; Guo, X.; Duan, W.; Wang, X.; Du, J. Accelerated solvent extraction of monacolin K from red yeast rice and purification by high-speed counter-current chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878, 2881–2885. [CrossRef]
51. Su, Y.C.; Wang, J.J.; Lin, T.T.; Pan, T.M. Production of the secondary metabolites γ-aminobutyric acid and monacolin K by Monascus. J. Ind. Microbiol. Biotechnol. 2003, 30, 41–46. [CrossRef]
52. Li, Y.G.; Liu, H.; Wang, Z.T. A validated stability-indicating HPLC with photodiode array detector (PDA) method for the stress tests of Monascus purpureus-fermented rice, red yeast rice. J. Pharm. Biomed. Anal. 2005, 39, 82–90. [CrossRef]
53. Theunis, M.; Naessens, T.; Verhoeven, V.; Hermans, N.; Apers, S. Development and validation of a robust high-performance liquid chromatographic method for the analysis of monacolins in red yeast rice. Food Chem. 2017, 234, 33–37. [CrossRef]
54. Omm, S. A New HPLC Method for Analysis of Natural Monacolin K in Red Yeast Rice Pharmaceutical Preparations. J. Pharmaceuton Nat. Prod. 2016, 1, 1. [CrossRef]
55. Heber, D.; Lembertas, A.; Lu, Q.Y.; Bowerman, S.; Go, V.L. An analysis of nine proprietary Chinese red yeast rice dietary supplements: Implications of variability in chemical profile and contents. J. Altern. Complement. Med. 2001, 7, 133–139. [CrossRef]
56. Li, M.; Fan, L.Y.; Zhang, W.; Sun, J.; Cao, C.X. Quantitative analysis ofLovastatin in capsule of Chinese medicine Monascus by capillary zone electrophoresis with UV–vis detector. J. Pharm. Biomed. Anal. 2007, 43, 387–392. [CrossRef]
57. Lucie, N.; Petr, C.; František, Š.; Hana, S. Fully automated method based on on-line molecularly imprinted polymer solid-phase extraction for determination of lovastatin in dietary supplements containing red yeast rice. Anal. Bioanal. Chem. 2019, 411, 1219–1228.
58. Eren, T.; Atar, N.; Yola, M.L.; Karimi-Maleh, H. A sensitive molecularly imprinted polymer based quartz crystal microbalance nanosensor for selective determination of lovastatin in red yeast rice. Food Chem. 2015, 185–430. [CrossRef]
59. Nigović, B.; Završki, M.; Sertić, M.; Mornar, A. Simple and Fast Voltammetric Method for Assaying Monacolin K in Red Yeast Rice Formulated Products. Food Anal. Methods 2015, 8, 180–188. [CrossRef]
60. Song, F.; El-Demerdash, A.; Lee, S.J.; Smith, R.E. Fast screening of lovastatin in red yeast rice products by flow injection tandem mass spectrometry. J. Pharm. Biomed. Anal. 2012, 57, 76–81. [CrossRef]
61. Jirasatid, S.; Nopharatana, M.; Kitsubun, P.; Tongta, A. Degradation kinetics of monacolin K in red yeast rice powder using multiresponse modeling approach. J. Food Eng. 2013, 116, 436–443. [CrossRef]
62. Gum, S.I.; Nguyen, P.A.; Lee, J.R.; Han, Y.H.; Cho, M.K. The physico-chemical alteration of lovastatin and enhanced antioxidant effect of Bacillus subtilis fermented-red yeast rice product. *Food Chem.* 2017, 232, 203–209. [CrossRef]

63. Huang, H.N.; Hua, Y.Y.; Bao, G.R.; Xie, L.H. The quantification of monacolin K in some red yeast rice from Fujian province and the comparison of the other product. *Chem. Pharm. Bull.* 2006, 54, 687–689. [CrossRef]

64. Ajdari, Z.; Ebrahimpour, A.; Abdul, M.M.; Hamid, M. Assessment of Monacolin in the Fermented Products Using *Monascus purpureus* ITCC391. *J. Biomed. Biotechnol.* 2011, 1–9.

65. Chen, C.H.; Uang, Y.S.; Wang, S.T.; Yang, J.C.; Lin, C.J. Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. *J. Evid. Based Complementary Altern. Med.* 2012, 2012, 1–10. [CrossRef]

66. Chen, C.H.; Uang, Y.S.; Wang, S.T.; Yang, J.C.; Lin, C.J. Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. *J. Evid. Based Complementary Altern. Med.* 2012, 2012, 1–10. [CrossRef]

67. Huang, Z.; Xu, Y.; Li, Y.; Wang, Y. Conversion investigation for lovastatin and its derivatives by HPLC. *J. Chromatogr. Sci.* 2010, 48, 631–636. [CrossRef]

68. Donna, L.; Bartella, L.; Napoli, A.; Sindona, G.; Mazzotti, F. Assay of lovastatin containing dietary supplement by LC-MS/MS under MRM condition. *J. Mass Spectrom.* 2018, 53, 811–816. [CrossRef]

69. Svoboda, P.; Sander, D.; Plachká, K.; Nováková, L. Development of matrix effect-free MISPE-UHPLC–MS/MS method for determination of lovastatin in Pu-erh tea, oyster mushroom, and red yeast rice. *J. Pharm. Biomed. Anal.* 2017, 140, 367–376. [CrossRef]

70. Mornar, A.; Sertić, M.; Nigović, B. Development of a Rapid LC/DAD/FLD/MS Method for the Simultaneous Determination of Monacolins and Citrinin in Red Fermented Rice Products. *J. Agric. Food Chem.* 2013, 61, 1072–1080. [CrossRef]

71. Avula, B.; Cohen, P.A.; Wang, Y.H.; Sagi, S.; Feng, W.; Wang, M.; Khan, I.A. Chemical profiling and quantification of monacolins and citrinin in red yeast rice commercial raw materials and dietary supplements using liquid chromatography-accurate QToF mass spectrometry: Chemometrics application. *J. Pharm. Biomed. Anal.* 2014, 100, 243–253. [CrossRef]

72. Zhou, G.; Fu, L.; Li, X. Optimisation of ultrasound-assisted extraction conditions for maximal recovery of active monacolins and removal of toxic citrinin from red yeast rice by a full factorial design coupled with response surface methodology. *Food Chem.* 2015, 170, 186–192. [CrossRef]

73. Venhuis, B.J.; van Hunsel, F.; van de Koppel, S.; Keizers, P.H.J.; Jeurissen, S.M.F.; De Kaste, D. Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report. *Drug Test. Anal.* 2016, 8, 315–318. [CrossRef]

74. Lachenmeier, D.W.; Monakhova, Y.B.; Kuballa, T.; Löbell-Behrends, S.; Maixner, S.; Kohl-Himmelseher, M.; Waldner, A.; Steffen, C. NMR evaluation of total statin content and HMG CoA reductase inhibition in red yeast rice (*Monascus spp.*) food supplements. *Chin. Med.* 2012, 7, 8. [CrossRef]

75. Ma, J.; Li, Y.; Ye, Q.; Li, J.; Hua, Y.; Ju, D.; Zhang, D.; Cooper, R.; Chang, M. Constituents of red yeast rice, a traditional Chinese food and medicine. *J. Agric Food Chem.* 2000, 48, 5220–5225. [CrossRef]

76. Nigović, B.; Sertić, M.; Mornar, A. Simultaneous determination of lovastatin and citrinin in red yeast rice supplements by micellar electrokinetic capillary chromatography. *Food Chem.* 2013, 138, 531–538. [CrossRef]

77. Bule, M.; Khan, F.; Niaz, K. Red Yeast Rice (*Monascus purpureus*). In *Nonvitamin and Nonmineral Nutritional Supplements*, 1st ed.; Nabavi, S.M., Silva, A.S., Eds.; Elsevier: Amsterdam, The Netherlands, 2019; pp. 509–515.

78. Poli, A.; Barbagallo, C.M.; Cicero, A.F.G.; Corsini, A.; Manzato, E.; Trimarco, B.; Marangoni, F. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. *Pharmacol. Res.* 2018, 134, 51–60. [CrossRef]

79. The Pharmaceutical Society of Britain. *Martindale: The Complete Drug Reference (37th edition)*; The Pharmaceutical Press: Britain, UK, 2015; p. 2319.

80. Chinese Pharmacopoeia Commission. *Pharmacopoeia of the People’s Republic of China Part. I*; People’s Medical Publishing House: Beijing, China, 2015; pp. 859–861.

81. Light Industry Standardization Commission. *People’s Republic of China Light Industry Standard: Functional red yeast rice QB/T 2847-2007*; China Light Industry Press: Beijing, China, 2007; p. 8. (In Chinese)

82. Chinese Medicine Standards Commission of Yunnan Province. *The standard of Chinese herbal medicine of Yunnan Province;* Yunnan Science and Technology Press: Yunnan, China, 2005; p. 25. (In Chinese)
83. Chinese Medicine Standards Commission of Fujian Province. The standard of Chinese herbal medicine of Fujian Province; Fujian Science and Technology Press: Fujian, China, 2009; p. 101. (In Chinese)

84. Chinese Medicine Standards Commission of Henan Province. The standard of Chinese herbal medicine of Henan Province; Henan Science and Technology Press: Henan, China, 1991; p. 41. (In Chinese)

85. Chinese Medicine Standards Commission of Hubei Province. The standard of Chinese herbal medicine of Hubei Province; Hubei Science and Technology Press: Hubei, China, 2009; p. 60. (In Chinese)

86. Chinese Medicine Standards Commission of Beijing. The standard of Chinese herbal medicine of Beijing; Beijing Science and Technology Press: Beijing, China, 1998; p. 119. (In Chinese)

87. Chinese Medicine Standards Commission of Shandong Province. The standard of Chinese herbal medicine of Shandong Province; Shandong Science and Technology Press: Shandong, China, 2012; p. 110. (In Chinese)

88. Sichuan Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Sichuan Province; Sichuan Science and Technology Press: Chengdu, China, 2016; pp. 175–177. (In Chinese)

89. Zhejiang Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Zhejiang Province; China Medical Science and Technology Press: Beijing, China, 2015; pp. 127–128. (In Chinese)

90. Hunan Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Hunan Province; Hunan Science and Technology Press: Changsha, China, 2010; p. 502. (In Chinese)

91. Heilongjiang Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Heilongjiang Province; Heilongjiang Science and Technology Press: Haerbin, China, 2012; p. 149. (In Chinese)

92. Hebei Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Hebei Province; Hebei Science and Technology Press: Tianjin, China, 2003; p. 64. (In Chinese)

93. Beijing Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Beijing Province; China Medical Science and Technology Press: Beijing, China, 2008; p. 234. (In Chinese)

94. Chongqing Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Chongqing; Chongqing Science and Technology Press: Chongqing, China, 2008; p. 138. (In Chinese)

95. Shanghai Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Shanghai; Shanghai Science and Technology Press: Shanghai, China, 2008; p. 183. (In Chinese)

96. Shandong Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Shandong Province; Shandong Science and Technology Press: Shandong, China, 2012; p. 268. (In Chinese)

97. Henan Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Henan Province; Henan Science and Technology Press: Henan, China, 2005; p. 529. (In Chinese)

98. Tianjin Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Tianjin; Tianjin Science and Technology Press: Tianjin, China, 2005; p. 377. (In Chinese)

99. Fujian Food and Drug Administration. Standard for Chinese Herbal Medicine Processing of Fujian Province; Fujian Science and Technology Press: Fujian, China, 2012; p. 89. (In Chinese)

100. Nannoni, G.; Ali, A.; Di Pierro, F. Development of a new highly standardized and granulated extract from Monascus purpureus with a high content of monacolin K and KA and free of inactive secondary monacolins and citrinin. Nutrafoods 2015, 14, 197–205. [CrossRef]

101. Perini, M.; Carbone, G.; Camin, F. Stable isotope ratio analysis for authentication of red yeast rice. Talanta 2017, 174, 228–233. [CrossRef]

102. Suzuki, Y.; Chikaraishi, Y.; Ogawab, N.O.; Ohkouchi, N.; Korenaga, T. Geographical origin of polished rice based on multiple element and stable isotope analyses. Food Chem. 2008, 109, 470–475. [CrossRef]

103. Peng, W.; Shen, H.; Lin, B.; Han, P.; Li, C.; Zhang, Q.; Ye, B.; Rahman, K.; Xin, H.; Qin, L.; et al. Docking study and antiosteooporosis effects of a dibenzylbutane lignan isola Qin ted from Litsea cubeba and antiosteoporosis effects of a dibenzylbutane lignan isola Qin ted from Litsea cubeba. Food Chem. 2015, 174, 228–233. [CrossRef]

104. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 2016, 79, 629–661. [CrossRef]

105. Liu, C.; Guo, D.; Liu, L. Quality transitivity and traceability system of herbal medicine products based on quality markers. Phytomedicine 2018, 44, 247–257. [CrossRef]

106. Zhang, X.Y.; Liu, J.S.; Gao, S.M.; Chen, R.C.; Qi, Y.D.; Zhang, B.G.; Liu, H.T.; Xiao, P.G. Research methods and applications progress on spectrum-effect relationships in study of Traditional Chinese Medicine. Chin. J. Chin. Mater. Med. 2019, 1, 1–12. [CrossRef]

107. Cai, L.; Zhang, Q.; Yang, F.Q. Applications progress on spectrum-effect relationship in study of Chinese materia medica. Chin. Tradit. Herb. Drugs. 2017, 48, 5005–5011.
108. Shi, M.J.; Zhang, Y.; Song, M.M.; Sun, Y.; Li, C.Q.; Kang, W.Y. Screening the marker components in *Psoralea corylifolia* L. with the aids of spectrum-effect relationship and component knock-out by UPLC-MS². *Int. J. Mol. Sci.* 2018, 19, 3439. [CrossRef]

109. Xiao, R.Y.; Wu, L.J.; Hong, X.X.; Tao, L.; Luo, P.; Shen, X.C. Screening of analgesic and anti-inflammatory active component in Fructus Alpiniae zerumbet based on spectrum-effect relationship and GC-MS. *Biomed. Chromatogr.* 2018, 32, e4112. [CrossRef]

110. Liu, C.X.; Chen, S.L.; Xiao, X.H.; Zhang, T.J.; Hou, W.B.; Liao, M.L. A new concept on quality marker of Chinese materia medica: Quality control for Chinese medicinal products. *Chin. Tradit. Herb. Drugs.* 2016, 47, 1443–1457.

111. Cao, G.Z.; Yuan, Z.H. Innovation System of Chinese Traditional Medicine Materials Traceability Based on Block Chain. *Modern Chin. Med.* 2018, 20, 1465–1470.

112. Shi, M.Y.; Hu, L.; Ou, R.T.; Zhao, Y.T.; Wen, C.Q. Research of Quality Traceability System of Traditional Chinese Medicine. *Asia-Pacific Tradit. Med.* 2018, 14, 75–77.

113. Liu, C.X.; Cheng, Y.Y.; Guo, D.A.; Zhang, T.J.; Li, Y.Z.; Hou, W.B.; Huang, L.Q.; Xu, H.Y. A new concept on quality marker for quality assessment and process control of Chinese medicines. *Chin. Herb. Med.* 2017, 9, 3–13. [CrossRef]

114. Sheng, G.L. Design of Electronic Coding Scheme for Quality Traceability of Radix Paeoniae Alba Decoction Pieces. *J. Taiyuan Univ. (Nat. Sci. Ed.)* 2019, 37, 83–86.

115. Zhou, M.; Ma, X.; Ding, G.; Wang, Z.; Liu, D.; Tong, Y.; Zhou, H.; Gao, J.; Hou, Y.; Jiang, M.; et al. Comparison and evaluation of antimuscarinic and anti-inflammatory effects of five Bulbus fritillariae species based on UPLC-Q/TOF integrated dual-luciferase reporter assay, PCA and ANN analysis. *J. Chromatogr. B* 2017, 1041–1042, 60–69. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).